Target intelligence / Profile preview

Interferon regulatory factor-responsive elements in the Programmed death-ligand 1 promoter (IRF-REs (PD-L1))

Target
IRF-REs (PD-L1)
Molecular classification
DNA regulatory element, Promoter
01

Overview

The IRF-responsive DNA elements in the PD-L1 promoter are specific genomic sequences located within the regulatory region of the CD274 gene, which encodes the Programmed death-ligand 1 (PD-L1) protein. These elements, primarily consisting of two Interferon-Stimulated Response Elements (ISREs) termed IRF-E1 and IRF-E2, serve as critical docking sites for transcription factors such as IRF1 and IRF3 (Garcia-Diaz et al., 2017, Cell Reports). In the tumor microenvironment, the production of interferon-gamma by T cells triggers the JAK/STAT signaling pathway, leading to the upregulation of IRF1, which then binds to these DNA elements to drive PD-L1 transcription (Bellucci et al., 2015, Oncoimmunology). This mechanism, known as adaptive immune resistance, allows cancer cells to suppress anti-tumor immune responses by engaging the PD-1 receptor on T cells. While these DNA elements are not traditional protein targets, they represent a pivotal node in immune checkpoint regulation. Therapeutic strategies aimed at disrupting the interaction between IRFs and these promoter elements, such as decoy oligonucleotides or inhibitors of upstream signaling (e.g., JAK inhibitors), are areas of active research to overcome resistance to immunotherapy (Lu et al., 2017, Cancer Letters).

Other names
ISRE in CD274 promoterIRF-binding sites in PD-L1 promoterInterferon-stimulated response elements of PD-L1IRF-E1 and IRF-E2
02

Mechanism of action

Acts as a transcriptional regulatory site where Interferon Regulatory Factors (primarily IRF1) bind to induce the expression of the CD274 (PD-L1) gene in response to interferon signaling.

03

Biological functions

Regulation of gene expressionImmune responseInterferon signalingAdaptive immune resistance
04

Disease associations

CancerInflammationInfectionAutoimmune disease
05

Safety considerations

Potential for broad suppression of the interferon responseOff-target transcriptional changes in other interferon-stimulated genesRisk of increased susceptibility to viral infectionsPotential for autoimmunity if constitutively inhibited
06

Biomarkers

PD-L1 protein expressionIRF1 mRNA levelsSTAT1 phosphorylation statusInterferon-gamma signature

Beyond the preview

Go deeper on Interferon regulatory factor-responsive elements in the Programmed death-ligand 1 promoter (IRF-REs (PD-L1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interferon regulatory factor-responsive elements in the Programmed death-ligand 1 promoter (IRF-REs (PD-L1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call